<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-05036174</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-16T19:42:38+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials</title>
            <author role="aut">
              <persName>
                <forename type="first">Julien</forename>
                <surname>Mazieres</surname>
              </persName>
              <email type="md5">5fc5b0b2eb82d644afecc289fe088c4b</email>
              <email type="domain">chu-toulouse.fr</email>
              <idno type="idhal" notation="numeric">1033301</idno>
              <idno type="halauthorid" notation="string">1334349-1033301</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-5921-7613</idno>
              <affiliation ref="#struct-450027"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Achim</forename>
                <surname>Rittmeyer</surname>
              </persName>
              <idno type="halauthorid">1388664-0</idno>
              <affiliation ref="#struct-1096148"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Shirish</forename>
                <surname>Gadgeel</surname>
              </persName>
              <idno type="halauthorid">1817967-0</idno>
              <affiliation ref="#struct-447514"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Toyoaki</forename>
                <surname>Hida</surname>
              </persName>
              <idno type="halauthorid">3483205-0</idno>
              <affiliation ref="#struct-116614"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">David</forename>
                <surname>Gandara</surname>
              </persName>
              <idno type="halauthorid">3483206-0</idno>
              <affiliation ref="#struct-73743"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Diego</forename>
                <surname>Cortinovis</surname>
              </persName>
              <idno type="halauthorid">2844925-0</idno>
              <affiliation ref="#struct-1087059"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Fabrice</forename>
                <surname>Barlesi</surname>
              </persName>
              <idno type="halauthorid">361833-0</idno>
              <affiliation ref="#struct-179570"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Wei</forename>
                <surname>Yu</surname>
              </persName>
              <idno type="halauthorid">2540634-0</idno>
              <affiliation ref="#struct-98288"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Christina</forename>
                <surname>Matheny</surname>
              </persName>
              <idno type="halauthorid">3483207-0</idno>
              <affiliation ref="#struct-98288"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Marcus</forename>
                <surname>Ballinger</surname>
              </persName>
              <idno type="halauthorid">3483208-0</idno>
              <affiliation ref="#struct-98288"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Keunchil</forename>
                <surname>Park</surname>
              </persName>
              <idno type="halauthorid">561067-0</idno>
              <affiliation ref="#struct-457021"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Accord Elsevier</forename>
                <surname>CCSD</surname>
              </persName>
              <email type="md5">3cc0cc7b8e3329bfb7423fa2578d788e</email>
              <email type="domain">ccsd.cnrs.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2025-07-09 10:41:09</date>
              <date type="whenModified">2026-04-21 09:42:24</date>
              <date type="whenReleased">2025-07-09 10:41:11</date>
              <date type="whenProduced">2021-01</date>
              <date type="whenEndEmbargoed">2021-12-28</date>
              <ref type="file" target="https://hal.science/hal-05036174v1/document">
                <date notBefore="2021-12-28"/>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://hal.science/hal-05036174v1/file/S1556086420308029.pdf" id="file-5153308-4449659">
                <date notBefore="2021-12-28"/>
              </ref>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="1081876">
                <persName>
                  <forename>Accord Elsevier</forename>
                  <surname>CCSD</surname>
                </persName>
                <email type="md5">3cc0cc7b8e3329bfb7423fa2578d788e</email>
                <email type="domain">ccsd.cnrs.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-05036174</idno>
            <idno type="halUri">https://hal.science/hal-05036174</idno>
            <idno type="halBibtex">mazieres:hal-05036174</idno>
            <idno type="halRefHtml">&lt;i&gt;Journal of Thoracic Oncology&lt;/i&gt;, 2021, 16 (1), pp.140-150. &lt;a target="_blank" href="https://dx.doi.org/10.1016/j.jtho.2020.09.022"&gt;&amp;#x27E8;10.1016/j.jtho.2020.09.022&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Journal of Thoracic Oncology, 2021, 16 (1), pp.140-150. &amp;#x27E8;10.1016/j.jtho.2020.09.022&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 - Attribution - Non-commercial use<ref corresp="#file-5153308-4449659"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="UNIV-TLSE3">Université de Toulouse</idno>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="UNIV-AMU">Aix Marseille Université</idno>
            <idno type="stamp" n="IGR" corresp="FNCLCC">Institut Gustave Roussy</idno>
            <idno type="stamp" n="CRCM">Centre de Recherche en Cancérologie de Marseille</idno>
            <idno type="stamp" n="ELSEVIER">Import Elsevier</idno>
            <idno type="stamp" n="UNIV-UT3">Université Toulouse 3</idno>
            <idno type="stamp" n="UT3-INP">Université de Toulouse / Toulouse INP</idno>
            <idno type="stamp" n="UT3-TOULOUSEINP">Université de Toulouse / Toulouse INP</idno>
            <idno type="stamp" n="CRCT">CRCT</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Julien</forename>
                    <surname>Mazieres</surname>
                  </persName>
                  <email type="md5">5fc5b0b2eb82d644afecc289fe088c4b</email>
                  <email type="domain">chu-toulouse.fr</email>
                  <idno type="idhal" notation="numeric">1033301</idno>
                  <idno type="halauthorid" notation="string">1334349-1033301</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-5921-7613</idno>
                  <affiliation ref="#struct-450027"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Achim</forename>
                    <surname>Rittmeyer</surname>
                  </persName>
                  <idno type="halauthorid">1388664-0</idno>
                  <affiliation ref="#struct-1096148"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Shirish</forename>
                    <surname>Gadgeel</surname>
                  </persName>
                  <idno type="halauthorid">1817967-0</idno>
                  <affiliation ref="#struct-447514"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Toyoaki</forename>
                    <surname>Hida</surname>
                  </persName>
                  <idno type="halauthorid">3483205-0</idno>
                  <affiliation ref="#struct-116614"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">David</forename>
                    <surname>Gandara</surname>
                  </persName>
                  <idno type="halauthorid">3483206-0</idno>
                  <affiliation ref="#struct-73743"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Diego</forename>
                    <surname>Cortinovis</surname>
                  </persName>
                  <idno type="halauthorid">2844925-0</idno>
                  <affiliation ref="#struct-1087059"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Fabrice</forename>
                    <surname>Barlesi</surname>
                  </persName>
                  <idno type="halauthorid">361833-0</idno>
                  <affiliation ref="#struct-179570"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Wei</forename>
                    <surname>Yu</surname>
                  </persName>
                  <idno type="halauthorid">2540634-0</idno>
                  <affiliation ref="#struct-98288"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Christina</forename>
                    <surname>Matheny</surname>
                  </persName>
                  <idno type="halauthorid">3483207-0</idno>
                  <affiliation ref="#struct-98288"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Marcus</forename>
                    <surname>Ballinger</surname>
                  </persName>
                  <idno type="halauthorid">3483208-0</idno>
                  <affiliation ref="#struct-98288"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Keunchil</forename>
                    <surname>Park</surname>
                  </persName>
                  <idno type="halauthorid">561067-0</idno>
                  <affiliation ref="#struct-457021"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">33958</idno>
                <idno type="issn">1556-0864</idno>
                <idno type="eissn">1556-1380</idno>
                <title level="j">Journal of Thoracic Oncology</title>
                <imprint>
                  <publisher>Lippincott, Williams &amp; Wilkins</publisher>
                  <biblScope unit="volume">16</biblScope>
                  <biblScope unit="issue">1</biblScope>
                  <biblScope unit="pp">140-150</biblScope>
                  <date type="datePub">2021-01</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1016/j.jtho.2020.09.022</idno>
              <idno type="pii">S1556-0864(20)30802-9</idno>
              <idno type="pubmed">33166718</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en">Overall survival</term>
                <term xml:lang="en">Non–small cell lung cancer</term>
                <term xml:lang="en">Docetaxel</term>
                <term xml:lang="en">Atezolizumab</term>
              </keywords>
              <classCode scheme="mesh">Antibodies, Monoclonal*</classCode>
              <classCode scheme="mesh">Antibodies, Monoclonal, Humanized</classCode>
              <classCode scheme="mesh">Docetaxel*</classCode>
              <classCode scheme="mesh">Humans</classCode>
              <classCode scheme="mesh">Lung Neoplasms* / drug therapy</classCode>
              <classCode scheme="halDomain" n="sdv.can">Life Sciences [q-bio]/Cancer</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>&lt;b&gt;Introduction: &lt;/b&gt;The phase 2 POPLAR and phase 3 OAK studies of the anti-programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab in patients with previously treated advanced NSCLC revealed significant improvements in survival versus docetaxel (p = 0.04 and 0.0003, respectively). Longer follow-up permits evaluation of continued benefit of atezolizumab. This study reports the final overall survival (OS) and safety findings from both trials.&lt;b&gt;Methods: &lt;/b&gt;POPLAR randomized 287 patients (atezolizumab, 144; docetaxel, 143) and OAK randomized 1225 patients (atezolizumab, 613; docetaxel, 612). The patients received atezolizumab (1200 mg fixed dose) or docetaxel (75 mg/m2) every 3 weeks. Efficacy and safety outcomes were evaluated.&lt;b&gt;Results: &lt;/b&gt;A longer OS was observed in patients receiving atezolizumab versus docetaxel in POPLAR (median OS = 12.6 mo versus 9.7 mo; hazard ratio = 0.76, 95% confidence interval [CI]: 0.58-1.00) and OAK (median OS = 13.3 versus 9.8 mo; hazard ratio = 0.78, 95% CI: 0.68-0.89). The 4-year OS rates in POPLAR were 14.8% (8.7-20.8) and 8.1% (3.2-13.0) and those in OAK were 15.5% (12.4-18.7) and 8.7% (6.2-11.3) for atezolizumab and docetaxel, respectively. Atezolizumab had improved OS benefit compared with docetaxel across all PD-L1 expression and histology groups. Most 4-year survivors in the docetaxel arms received subsequent immunotherapy (POPLAR, 50%; OAK, 65%). Of the 4-year survivors, most had Eastern Cooperative Oncology Group performance status of 0 and nonsquamous histological classification and approximately half were responders (POPLAR: atezolizumab, seven of 15; docetaxel, three of four; OAK: atezolizumab, 24 of 43; docetaxel, 11 of 26). Treatment-related grade 3/4 adverse events occurred in 27% and 16% of atezolizumab 4-year survivors in POPLAR and OAK, respectively.&lt;b&gt;Conclusions:&lt;/b&gt; Long-term follow-up suggests a consistent survival benefit with atezolizumab versus docetaxel in patients with previously treated NSCLC regardless of PD-L1 expression, histology, or subsequent immunotherapy. Atezolizumab had no new safety signals, and the safety profile was similar to that in previous studies.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="regrouplaboratory" xml:id="struct-450027" status="OLD">
          <idno type="ROR">https://ror.org/014hxhm89</idno>
          <orgName>Institut Universitaire du Cancer de Toulouse - Oncopole</orgName>
          <orgName type="acronym">IUCT Oncopole - UMR 1037</orgName>
          <desc>
            <address>
              <addrLine>Av. Irène Joliot-Curie 31100 Toulouse</addrLine>
              <country key="FR"/>
            </address>
          </desc>
          <listRelation>
            <relation active="#struct-217752" type="direct"/>
            <relation active="#struct-443875" type="indirect"/>
            <relation active="#struct-300075" type="direct"/>
            <relation active="#struct-303623" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-1096148" status="INCOMING">
          <orgName>Lungenfachklinik Immenhausen</orgName>
          <desc>
            <address>
              <addrLine>Robert-Koch-Straße 3, 34376 Immenhausen</addrLine>
              <country key="DE"/>
            </address>
          </desc>
        </org>
        <org type="institution" xml:id="struct-447514" status="VALID">
          <idno type="ROR">https://ror.org/0193sb042</idno>
          <orgName>Henry Ford Hospital</orgName>
          <desc>
            <address>
              <addrLine>2799 West Grand Blvd., Detroit, MI 48202-2689.</addrLine>
              <country key="US"/>
            </address>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-116614" status="INCOMING">
          <orgName>Aichi Cancer Center Hospital</orgName>
          <desc>
            <address>
              <addrLine>Nagoya</addrLine>
              <country key="FR"/>
            </address>
          </desc>
          <listRelation>
            <relation active="#struct-310716" type="direct"/>
          </listRelation>
        </org>
        <org type="laboratory" xml:id="struct-73743" status="INCOMING">
          <orgName>Davis Cancer Center</orgName>
          <desc>
            <address>
              <addrLine>4645 2nd Avenue Sacramento, CA 95817,</addrLine>
              <country key="US"/>
            </address>
          </desc>
          <listRelation>
            <relation active="#struct-320813" type="direct"/>
            <relation active="#struct-471291" type="indirect"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-1087059" status="VALID">
          <orgName>San Gerardo Hospital Company Monza</orgName>
          <orgName type="acronym">SGH</orgName>
          <desc>
            <address>
              <addrLine>Via G. B. Pergolesi, 33, 20900 Monza MB</addrLine>
              <country key="IT"/>
            </address>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-179570" status="VALID">
          <idno type="RNSR">201220152G</idno>
          <idno type="ROR">0494jpz02</idno>
          <orgName>Centre de Recherche en Cancérologie de Marseille</orgName>
          <orgName type="acronym">CRCM</orgName>
          <date type="start">2012</date>
          <desc>
            <address>
              <addrLine>27 bd Leï Roure, BP 30005913273 Marseille Cedex 09</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://crcm.marseille.inserm.fr/spip.php?article314</ref>
          </desc>
          <listRelation>
            <relation name="UM105" active="#struct-198056" type="direct"/>
            <relation name="UMR7258" active="#struct-301325" type="direct"/>
            <relation active="#struct-301051" type="indirect"/>
            <relation name="U1068" active="#struct-303623" type="direct"/>
            <relation name="UMR7258" active="#struct-441569" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-98288" status="VALID">
          <orgName>Genentech, Inc.</orgName>
          <desc>
            <address>
              <addrLine>1 DNA Way South San Francisco, CA 94080-4990</addrLine>
              <country key="US"/>
            </address>
            <ref type="url">http://www.gene.com/gene/index.jsp</ref>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-457021" status="VALID">
          <orgName>Samsung Medical Center Sungkyunkwan University School of Medicine</orgName>
          <desc>
            <address>
              <country key="KR"/>
            </address>
          </desc>
          <listRelation>
            <relation active="#struct-457020" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-217752" status="OLD">
          <idno type="IdRef">026404672</idno>
          <idno type="ISNI">0000000121617331</idno>
          <idno type="ROR">https://ror.org/02v6kpv12</idno>
          <idno type="Wikidata">Q1273188</idno>
          <orgName>Université Toulouse III - Paul Sabatier</orgName>
          <orgName type="acronym">UT3</orgName>
          <date type="end">2025-01-01</date>
          <desc>
            <address>
              <addrLine>118 route de Narbonne - 31062 Toulouse</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-tlse3.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-443875" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-443875" status="VALID">
          <idno type="ROR">https://ror.org/017tgbk05</idno>
          <orgName>Communauté d'universités et établissements de Toulouse</orgName>
          <orgName type="acronym">Comue de Toulouse</orgName>
          <desc>
            <address>
              <addrLine>41 Allée Jules Guesde, 31000 Toulouse</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.univ-toulouse.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-300075" status="VALID">
          <orgName>Centre Hospitalier Universitaire de Toulouse</orgName>
          <orgName type="acronym">CHU Toulouse</orgName>
          <desc>
            <address>
              <addrLine>regroupe les hôpitaux  Purpan, Rangueil, Pierre-Paul Riquet, Larey, Paule de Viguier, Hôtel Dieu Saint-Jacques, La Grave, etc.</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.chu-toulouse.fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-310716" status="INCOMING">
          <orgName>Aichi Cancer Center Hospital</orgName>
          <desc>
            <address>
              <country key="FR"/>
            </address>
          </desc>
        </org>
        <org type="institution" xml:id="struct-320813" status="VALID">
          <idno type="IdRef">03243975X</idno>
          <idno type="ROR">https://ror.org/05rrcem69</idno>
          <orgName>University of California [Davis]</orgName>
          <orgName type="acronym">UC Davis</orgName>
          <date type="start">1905-01-01</date>
          <desc>
            <address>
              <addrLine>One Shields Avenue, , Davis, CA 95616-5294</addrLine>
              <country key="US"/>
            </address>
            <ref type="url">https://www.ucdavis.edu/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-471291" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-471291" status="VALID">
          <idno type="ROR">https://ror.org/00pjdza24</idno>
          <orgName>University of California</orgName>
          <orgName type="acronym">UC</orgName>
          <date type="start">1869-01-01</date>
          <desc>
            <address>
              <country key="US"/>
            </address>
            <ref type="url">https://www.universityofcalifornia.edu/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-198056" status="VALID">
          <idno type="IdRef">15863621X</idno>
          <idno type="ISNI">0000 0001 2176 4817</idno>
          <idno type="ROR">https://ror.org/035xkbk20</idno>
          <orgName>Aix Marseille Université</orgName>
          <orgName type="acronym">AMU</orgName>
          <date type="start">2012-01-01</date>
          <desc>
            <address>
              <addrLine>Aix-Marseille UniversitéJardins du Pharo58 Boulevard Charles Livon13284 Marseille cedex 7</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-amu.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-301325" status="VALID">
          <idno type="ROR">https://ror.org/04s3t1g37</idno>
          <orgName>Institut Paoli-Calmettes</orgName>
          <orgName type="acronym">IPC</orgName>
          <desc>
            <address>
              <addrLine>232 Boulevard de Sainte-Marguerite13009 Marseille</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.institutpaolicalmettes.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-301051" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-301051" status="VALID">
          <orgName>Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)</orgName>
          <desc>
            <address>
              <country key="FR"/>
            </address>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-457020" status="INCOMING">
          <orgName>Institute Division of Hematology/Oncology</orgName>
          <desc>
            <address>
              <country key="KR"/>
            </address>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>